News and Announcements
With 253,000 passengers to-date and >11,000 trips/month, Shebah is well on track to their IPO
- Published March 22, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
“Shebah does not just move people around, we need to be there for the women travelling at night, families requiring baby seats, vulnerable and elderly passengers, school children of working parents and for women who need a safe and flexible job opportunity.
As Australia’s leading all-women rideshare our vision is to ensure there is always a safe transport option for women and families. Whether you are investing to create a safer world or creating a piece of history that enables women to earn, learn and participate.”
George McEncroe, Founder, Shebah
Executive Summary
Shebah is Australia’s leading all-women ride share delivering the safest on demand solution car for women and children. A purpose-built tech platform that sets us apart.
Shebah is the go-to option with 253,000 passengers and the most highly vetted women drivers in Australia.
Investment Highlights
- Shebah is the biggest ever female based investment on a CSF platform.
- Shebah has the necessary approval to launch in New Zealand and plan to be operating there soon.
- 100 B2B clients & growing (15 onboarded in Jan 2021)
- >11,000 trips per month*
- Industry size: $693 million p.a with 13% expected growth
- Shebah has been Number 1 in the app store several times and is the first rideshare in Australia to transport pets.
Investment Offering
Shebah is raising $5 million to fund their next level of growth in an effort to take them to IPO.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
